Regeneron Pharmaceuticals ( (REGN) ) has released its Q1 earnings. Here is a breakdown of the information Regeneron Pharmaceuticals presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals, a leading biotechnology company, specializes in inventing, developing, and commercializing life-transforming medicines for serious diseases, with a focus on eye diseases, allergic and inflammatory diseases, cancer, and rare diseases. In its first quarter of 2025, Regeneron reported revenues of $3.0 billion, with a GAAP diluted EPS of $7.27 and a non-GAAP diluted EPS of $8.22. The company highlighted significant growth in Dupixent sales, a 54% increase in EYLEA HD U.S. net sales, and several regulatory approvals, including Dupixent for chronic spontaneous urticaria in the U.S. and COPD in Japan. Key financial metrics showed a 4% decrease in total revenues compared to the previous year, while GAAP net income increased by 12%. The company also announced strategic investments in infrastructure and manufacturing, expected to total over $7 billion. Looking ahead, Regeneron remains focused on advancing its clinical programs and maximizing long-term shareholder value through internal investments and share repurchases.